Company profile for DepYmed

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

DepYmed Inc., is a New York based cancer and rare disease therapeutic development company. DepYmed is currently developing potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) as potential novel therapeutics for HER2-positive breast cancer and Rett Syndrome. In addition to PTP1B inhibitors, DepYmed has developed a portfolio ofnovel small molecules with copper chelating properties which can be applied as pote...
DepYmed Inc., is a New York based cancer and rare disease therapeutic development company. DepYmed is currently developing potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) as potential novel therapeutics for HER2-positive breast cancer and Rett Syndrome. In addition to PTP1B inhibitors, DepYmed has developed a portfolio ofnovel small molecules with copper chelating properties which can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer. DepYmed continues to develop the next generation of more potent PTP1B inhibitors.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Farmingdale, New York
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com//en/news-release/2024/10/02/2957009/0/en/DepYmed-to-Present-at-the-9th-World-Rett-Syndrome-Congress.html

GLOBENEWSWIRE
02 Oct 2024

https://www.globenewswire.com/news-release/2024/03/19/2848739/0/en/DepYmed-Receives-Clearance-from-U-S-Food-and-Drug-Administration-to-Initiate-Phase-1-Clinical-Trial-for-DPM-1003-for-the-Treatment-of-Rett-Syndrome.html

GLOBENEWSWIRE
19 Mar 2024

https://www.globenewswire.com//news-release/2024/02/21/2832861/0/en/DepYmed-to-Meet-with-Investors-at-the-BIO-CEO-and-Investor-Conference.html

GLOBENEWSWIRE
21 Feb 2024

https://www.globenewswire.com//news-release/2024/02/07/2825316/0/en/DepYmed-to-Meet-with-Investors-at-the-34th-Annual-Oppenheimer-Healthcare-Life-Sciences-Conference.html

GLOBENEWSWIRE
07 Feb 2024

https://www.globenewswire.com//news-release/2023/10/03/2753800/0/en/DepYmed-to-Meet-with-Investors-at-the-Life-Sciences-Summit-in-New-York-City-October-11-2023.html

GLOBENEWSWIRE
03 Oct 2023

https://www.globenewswire.com//news-release/2023/09/27/2750519/0/en/DepYmed-to-Meet-with-Investors-at-the-BioFuture-Conference-in-New-York-City-October-4-6-2023.html

GLOBENEWSWIRE
27 Sep 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty